RecruitingPhase 1NCT06555744
A Study of ZW191 in Participants With Solid Tumors
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors
Sponsor
Zymeworks BC Inc.
Enrollment
145 participants
Start Date
Oct 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
- Measurable disease per RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- Adequate cardiac function: Cardiac left ventricular function, as defined by left ventricular ejection fraction (LVEF) ≥ 50% as determined by either echocardiogram (ECHO) or multigated acquisition scan (MUGA).
- Other adequate organ function.
Exclusion Criteria4
- Known additional malignancy that is progressing or requires active treatment or may interfere with study endpoints.
- Has received prior Topoisomerase I inhibitor(TOPO1i) antibody drug conjugate treatment, regardless of washout period.
- Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease.
- Severe chronic or active infections (including known active SARS-CoV-2 infection) requiring systemic therapy, including antibacterial, antifungal, or antiviral therapy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGZW191
Administered intravenously
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06555744
Related Trials
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT072087731 location
A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation
NCT070609892 locations
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT042224132 locations
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT0585336725 locations
A Study of the Safety and Efficacy of the Intravenous and Intratumoral Injection of OVV-01 in Patients With Advanced Solid Tumours.
NCT076484721 location